At the latest Indian Pharma Post E-Conference, leading experts identified faster regulatory approvals, infrastructure, digital innovation, investigator training, and public trust as critical pillars
The approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
Bolstering neuroscience push with late-stage Tourette therapy
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Samelisant will be the centerpiece of Suven’s scientific presence
Subscribe To Our Newsletter & Stay Updated
